RCEL AVITA Medical Inc
Price (delayed)
$10.31
Market cap
$267.95M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.95
Enterprise value
$294.77M
AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical's patented and proprietary collection
Highlights
The gross profit has grown by 26% year-on-year and by 7% since the previous quarter
The revenue has grown by 24% YoY and by 6% from the previous quarter
AVITA Medical's equity has shrunk by 65% YoY and by 27% QoQ
The net income has plunged by 63% YoY and by 11% from the previous quarter
Key stats
What are the main financial stats of RCEL
Market
Valuations
Earnings
Shares outstanding
25.99M
Market cap
$267.95M
Enterprise value
$294.77M
Price to earnings (P/E)
N/A
Price to book (P/B)
11.12
Price to sales (P/S)
4.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.42
Revenue
$54.41M
EBIT
-$45.91M
EBITDA
-$44.31M
Free cash flow
-$58.08M
Per share
Balance sheet
Liquidity
EPS
-$1.95
Free cash flow per share
-$2.25
Book value per share
$0.93
Revenue per share
$2.11
TBVPS
$3.39
Total assets
$87.83M
Total liabilities
$63.51M
Debt
$44.27M
Equity
$23.92M
Working capital
$59.17M
Debt to equity
1.85
Current ratio
5.29
Quick ratio
4.56
Net debt/EBITDA
-0.61
Margins
Efficiency
Dividend
EBITDA margin
-81.4%
Gross margin
86.2%
Net margin
-91.6%
Operating margin
-100%
Return on assets
-52.7%
Return on equity
-118.3%
Return on invested capital
-52.6%
Return on capital employed
-62%
Return on sales
-84.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RCEL stock price
How has the AVITA Medical stock price performed over time
Intraday
0.49%
1 week
13.67%
1 month
13.55%
1 year
-35.4%
YTD
-24.85%
QTD
30.18%
Financial performance
How have AVITA Medical's revenue and profit performed over time
Revenue
$54.41M
Gross profit
$46.88M
Operating income
-$54.41M
Net income
-$49.83M
Gross margin
86.2%
Net margin
-91.6%
The operating income has plunged by 66% YoY and by 9% from the previous quarter
The net income has plunged by 63% YoY and by 11% from the previous quarter
RCEL's operating margin is down by 34% YoY and by 3.1% from the previous quarter
RCEL's net margin is down by 32% year-on-year and by 5% since the previous quarter
Growth
What is AVITA Medical's growth rate over time
Valuation
What is AVITA Medical stock price valuation
P/E
N/A
P/B
11.12
P/S
4.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.42
The company's EPS has shrunk by 60% YoY and by 11% QoQ
The stock's price to book (P/B) is 101% more than its 5-year quarterly average of 5.5 and 29% more than its last 4 quarters average of 8.6
AVITA Medical's equity has shrunk by 65% YoY and by 27% QoQ
The P/S is 66% below the 5-year quarterly average of 14.2 and 26% below the last 4 quarters average of 6.6
The revenue has grown by 24% YoY and by 6% from the previous quarter
Efficiency
How efficient is AVITA Medical business performance
The return on assets has dropped by 63% year-on-year and by 11% since the previous quarter
AVITA Medical's return on equity has decreased by 41% QoQ
The company's return on sales fell by 22% YoY and by 2.8% QoQ
The ROIC has grown by 11% from the previous quarter and by 2.8% YoY
Dividends
What is RCEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RCEL.
Financial health
How did AVITA Medical financials performed over time
The total assets is 38% greater than the total liabilities
RCEL's quick ratio is down by 28% since the previous quarter and by 13% year-on-year
AVITA Medical's current ratio has decreased by 27% QoQ and by 6% YoY
RCEL's debt is 85% greater than its equity
AVITA Medical's equity has shrunk by 65% YoY and by 27% QoQ
RCEL's debt to equity is up by 37% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.